Kanamori H, Tanabe J, Okamoto R, Tamura T, Fujita H, Murata T, Hashimoto Y, Harano H, Matsuzaki M, Motomura S
First Department of Internal Medicine, Yokohama City University School of Medicine.
Rinsho Ketsueki. 1993 Jun;34(6):697-704.
Between 1981 and 1990, ACOMEP-BD regimen (adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide, prednisolone, bleomycin, dacarbazine) was compared with VEPA regimen (vincristine, cyclophosphamide, prednisolone, adriamycin) in 66 newly diagnosed patients younger than 65 of age, with non-Hodgkin's lymphoma (NHL). The median age of the patients was 47.5 years (range 22-64 years), 43 males and 23 females. One patients were in stage I, 6 were in II, 27 were in III, 32 were in IV. Twenty-seven patients received VEPA and 39 received ACOMEP-BD. The therapeutic results of 66 patients with ACOMEP-BD or VEPA were as follows: complete remission (CR) rate of 54% and 48%; relapse rate of 29% and 77%; CR duration of 2-34 months (mean: 22 months) and 2-74 months (16 months); freedom-from-relapse survival (at 3 years) of 71% and 38%; and overall survival (at 4 years) of 62% and 26%, respectively. In these results, only relapse rate was significant and the others were not. Prognostic factors were performance status (PS) and lactate dehydrogenase level for ACOMEP-BD, and PS and marrow involvement for VEPA. Received dose intensity was 0.85 in ACOMP-BD and 0.41 in VEPA. It was expected that outcome of patients with NHL can be improved by increasing dose intensity.
1981年至1990年间，对66例新诊断的年龄小于65岁的非霍奇金淋巴瘤（NHL）患者，比较了ACOMP - BD方案（阿霉素、环磷酰胺、长春新碱、甲氨蝶呤、依托泊苷、泼尼松龙、博来霉素、达卡巴嗪）与VEPA方案（长春新碱、环磷酰胺、泼尼松龙、阿霉素）。患者的中位年龄为47.5岁（范围22 - 64岁），男性43例，女性23例。1例患者处于I期，6例处于II期，27例处于III期，32例处于IV期。27例患者接受VEPA方案，39例接受ACOMP - BD方案。66例接受ACOMP - BD或VEPA方案治疗的患者的治疗结果如下：完全缓解（CR）率分别为54%和48%；复发率分别为29%和77%；CR持续时间分别为2 - 34个月（平均：22个月）和2 - 74个月（16个月）；无复发生存率（3年时）分别为71%和38%；总生存率（4年时）分别为62%和26%。在这些结果中，只有复发率有显著差异，其他无显著差异。ACOMP - BD方案的预后因素是体能状态（PS）和乳酸脱氢酶水平，VEPA方案的预后因素是PS和骨髓受累情况。ACOMP - BD方案的接受剂量强度为0.85，VEPA方案为0.41。预期通过增加剂量强度可改善NHL患者的预后。
